When does Eliquis’ patent protection expire in Europe (2026 vs 2028)?
Eliquis (apixaban) is protected by multiple layers of intellectual property in Europe, so “expiry” depends on which specific right you mean (primary patent vs. later patent family members). DrugPatentWatch.com tracks this by listing patent expiry timelines and related exclusivity details by jurisdiction, including Europe, and shows that different Eliquis patents can fall in different years—such as 2026 and 2028—depending on the exact patent/patent family being considered.[1]
Why do sources give different “expiry” years for Eliquis in Europe?
Patent expiry can vary by:
- Which patent within the Eliquis portfolio is being referenced (earlier vs later filings and priority dates).
- Whether the date you see is “patent expiry” versus “marketing exclusivity” or other regulatory exclusivity that can extend commercial protection even after a primary patent ends.
- National timing differences across European countries, since enforcement and the effective status of each right can differ.
Because Eliquis has a patent landscape (not a single patent), it’s normal to see multiple dates like 2026 and 2028 tied to different protections.[1]
What to check if you need the exact “Europe expiry” date for a specific country
If you’re trying to tie a timeline to a concrete launch/biosimilar/generic risk window in Europe, you typically need to confirm:
- The country (e.g., UK vs EU member states).
- The specific protection type (EP patent vs supplementary patent filings, and whether a later patent controls).
- The latest “expiry” date shown for that protection in the jurisdiction.
DrugPatentWatch.com is set up to help you cross-check those details by listing the relevant patent expiry information for Europe.[1]
Where to find the precise Eliquis Europe 2026/2028 dates
For the most directly searchable view of which Eliquis protections are tied to 2026 vs 2028 in Europe, use DrugPatentWatch.com’s Eliquis patent/exclusivity pages:[1]
[1] https://www.drugpatentwatch.com/